ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
84.055
-1.065 (-1.25%)
As of 12:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close85.120
Open85.430
Bid83.750 x 1100
Ask83.830 x 800
Day's range83.288 - 85.470
52-week range51.050 - 135.590
Volume131,462
Avg. volume704,621
Market cap2.487B
Beta2.03
PE ratio (TTM)N/A
EPS (TTM)-13.998
Earnings date30 Jul 2018 - 3 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est106.69
Trade prices are not sourced from all markets
  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool3 days ago

    3 Top Biotech Stocks to Buy Right Now

    These drug stocks are prescribing some serious growth potential in the years to come.

  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zacks7 days ago

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?
    Zacks14 days ago

    Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?

    Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Madrigal's NASH Study Data Encouraging, Stock Skyrockets
    Zacks20 days ago

    Madrigal's NASH Study Data Encouraging, Stock Skyrockets

    Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.

  • Analysts Are Bullish on Viking Therapeutics Stock
    Market Realist20 days ago

    Analysts Are Bullish on Viking Therapeutics Stock

    Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.

  • Forbes21 days ago

    Madrigal Pharma Shares Double After Successful Phase II Results For Fatty Liver Drug

    Madrigal Pharmaceuticals, the biotech company based in West Conshohocken, Pennsylvania, saw its share price rise more than 150% today after announcing a successful completion of its Phase II clinical trial to reduce nonalcoholic steatohepatitis (NASH). NASH, also known as fatty liver disease, is a disorder related to obesity and is steadily gaining prevalence throughout the developing world.

  • Madrigal Threatens Intercept's Lead in Fatty Liver Disease
    Bloomberg21 days ago

    Madrigal Threatens Intercept's Lead in Fatty Liver Disease

    Madrigal Pharmaceuticals Inc. more than doubled after a study of its new drug for a disease linked to obesity exceeded investor expectations. The results from a mid-stage study of the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, also pushed small-cap peer Viking Therapeutics Inc. higher while shares of Intercept Pharmaceuticals Inc., a drugmaker further along in NASH development, slid. Patients getting Madrigal’s experimental therapy known as MGL-3196 had a two-point reduction in a score that measures disease activity with a liver biopsy.

  • Bloomberg23 days ago

    Pharma Companies Race to Find Wonder Drug for Obesity-Linked Liver Disease

    The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: the fatty liver disease known as nonalcoholic steatohepatitis, or NASH. Madrigal Pharmaceuticals Inc. is expected to report results from a mid-stage study in NASH by Thursday. The drug developer is racing against peers like Intercept Pharmaceuticals Inc. to get its experimental therapy known as MGL-3196 to the market.

  • Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
    Zackslast month

    Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag

    Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.

  • Associated Presslast month

    Intercept: 1Q Earnings Snapshot

    The New York-based company said it had a loss of $3.22 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...

  • What's in Store for Intercept (ICPT) This Earnings Season?
    Zacks2 months ago

    What's in Store for Intercept (ICPT) This Earnings Season?

    Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).

  • Analysts’ Ratings for Amicus and Its Peers in April
    Market Realist2 months ago

    Analysts’ Ratings for Amicus and Its Peers in April

    Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.

  • How Analysts Rate Regenxbio and Peers in April 2018
    Market Realist2 months ago

    How Analysts Rate Regenxbio and Peers in April 2018

    Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).

  • Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?
    Investor's Business Daily2 months ago

    Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?

    CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.

  • A Look at Intercept Pharmaceuticals’ Cash Flows
    Market Realist2 months ago

    A Look at Intercept Pharmaceuticals’ Cash Flows

    Intercept Pharmaceuticals (ICPT) spent $265.4 million on operating activities in fiscal 2017 compared with $342.4 million in fiscal 2016. In fiscal 2017, Intercept Pharmaceuticals generated $2.8 million from financing activities, which were mainly from the exercise of options to purchase common stock. On April 5, 2018, Intercept Pharmaceuticals announced pricing of the upsized $250 million public offering of its common stock with a concurrent private placement of 1.5 million of its common shares.

  • 4 Top Stocks for Investing in Pharma's Next $35 Billion Market
    Motley Fool2 months ago

    4 Top Stocks for Investing in Pharma's Next $35 Billion Market

    A NASH dash is on -- and these drugmakers could come out on top.

  • Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
    Market Realist2 months ago

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.

  • Analysts’ Ratings For Acorda Therapeutics in April 2018
    Market Realist2 months ago

    Analysts’ Ratings For Acorda Therapeutics in April 2018

    Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.

  • The Financial Performance of Intercept Pharmaceuticals
    Market Realist2 months ago

    The Financial Performance of Intercept Pharmaceuticals

    Intercept Pharmaceuticals: An Investor’s Overview

  • 3 High-Growth Stocks That Could Soar
    Motley Fool2 months ago

    3 High-Growth Stocks That Could Soar

    Looking for stocks with explosive growth potential? Check these out.

  • An In- Depth Look at Intercept Pharmaceuticals’ Ocaliva
    Market Realist2 months ago

    An In- Depth Look at Intercept Pharmaceuticals’ Ocaliva

    Intercept Pharmaceuticals: An Investor’s Overview

  • Analysts’ Ratings for FibroGen and Its Peers in April 2018
    Market Realist2 months ago

    Analysts’ Ratings for FibroGen and Its Peers in April 2018

    FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.

  • Analysts’ Ratings for Intercept Pharmaceuticals in April
    Market Realist2 months ago

    Analysts’ Ratings for Intercept Pharmaceuticals in April

    Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Of the 20 analysts covering Intercept Pharmaceuticals in April 2018, ten of them have given the stock a “buy” or higher rating. Seven analysts have given it a “hold,” and three have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $110.91.

  • Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher
    Zacks2 months ago

    Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher

    Intercept Pharmaceuticals (ICPT) shares rose nearly 10% in the last trading session, amid huge volumes.

  • Why Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped Today
    Motley Fool3 months ago

    Why Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped Today

    Find out why these stocks helped lead the market higher.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes